PMA review goal of decision in 180 days for 75% of applications proposed in FDA's FY 1999 budget.
This article was originally published in The Gray Sheet
Executive Summary
PMA REVIEW GOAL OF 180 DAYS FOR 75% OF APPLICATIONS SET BY FDA for fiscal year 1999 (beginning Oct. 1), according to the Clinton Administration's FY 1999 budget proposal. "To speed the review process," FDA resolves to "review and process 75% of new medical device [PMAs] within 180 days, compared to 54% in 1996," the document reads.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.